Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.44 |
| ▸ | MERTK | Q12866 | 1/20 | 0.44 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 14/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL432301 | 0.84 | SYK (0.44) | SYKMAPK8MAPK9 | |
| SCHEMBL21554034 | 0.81 | SYK (0.57) | SYKMAPK8 | |
| SCHEMBL15337318 | 0.80 | MAPK8 (0.45) | SYKMAPK8MAPK9 | |
| SCHEMBL15321593 | 0.80 | MAPK8 (0.45) | SYKMAPK8MAPK9 | |
| SCHEMBL431462 | 0.79 | KMT2A (0.58) | FLT3TYRO3MERTKGAS6 | |
| SCHEMBL12411787 | 0.79 | CYP3A4 (0.40) | FLT3TYRO3MERTKGAS6MAPK8 | |
| SCHEMBL30121800 | 0.78 | SYK (0.65) | SYKMAPK8MAPK9 | |
| SCHEMBL20761123 | 0.78 | SYK (0.65) | SYKMAPK8MAPK9 | |
| SCHEMBL30496647 | 0.78 | SYK (0.61) | SYKMAPK8MAPK9 | |
| SCHEMBL26919488 | 0.78 | SYK (0.61) | SYKMAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595982-B1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2018-06-13 | — | — | EP | disclosed |
| US-9732070-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732070-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170152246-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2017-06-01 | — | — | US | disclosed |
| US-20170152246-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2017-06-01 | — | — | US | disclosed |
| US-9181222-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181222-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140329842-A1 | Protein Kinase C Inhibitors and Uses Thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329842-A1 | Protein Kinase C Inhibitors and Uses Thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| EP-2507227-B1 | TETRAZOLONES AS PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2014-10-08 | — | — | EP | disclosed |
| US-8710223-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710223-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20120022092-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2012-01-26 | — | — | US | disclosed |
| US-20120022092-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2012-01-26 | — | — | US | disclosed |
| WO-2012012619-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2011068898-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20110130415-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. | 2011-06-02 | — | — | US | disclosed |
| US-20110130415-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329842-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | FLT3 1016/4885TYRO3 1698/4885MERTK 927/4885 |
| US-20110130415-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | FLT3 1016/4885TYRO3 1698/4885MERTK 927/4885 |
| US-20120022092-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | FLT3 1016/4885TYRO3 1698/4885MERTK 927/4885 |
| US-20170152246-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | FLT3 1016/4885TYRO3 1698/4885MERTK 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.